Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cohance LifesciencesBOM:543064 -0.07%87 EBITDA Margin % is 12.97% as of Mar. 2026, which is 72% below its 10-year median of 46.46. GuruFocus rates BOM:543064 with a GF Score™ of 87/100 and a GF Value™ of ₹695.81 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, Cohance Lifesciences ranks better than 66.18% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cohance Lifesciences EBITDA Margin % Related Terms
Cohance Lifesciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cohance Lifesciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cohance Lifesciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cohance Lifesciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cohance Lifesciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cohance Lifesciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cohance Lifesciences (BOM:543064) has a EBITDA Margin % of 12.97% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cohance Lifesciences and its competitors. This is 72% below median its historical median of 46.46. Over the past decade, Cohance Lifesciences' EBITDA Margin % has ranged from 19.03 to 54.83. According to the industry distribution chart, Cohance Lifesciences ranks #325 out of 961 companies in the Drug Manufacturers industry, placing it in the top 33.8%.
Is Cohance Lifesciences' EBITDA Margin % too high?
Cohance Lifesciences' current EBITDA Margin % of 12.97% is 72% below median its 10-year median of 46.46. Over the past 10 years, this metric has ranged from a low of 19.03 to a high of 54.83. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Cohance Lifesciences' value of 12.97% is 4.3% above this industry median. Based on the distribution chart, Cohance Lifesciences ranks #325 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cohance Lifesciences has a GF Score™ of 87/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cohance Lifesciences' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cohance Lifesciences ranks #325 out of 961 companies for EBITDA Margin %. This puts Cohance Lifesciences in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Cohance Lifesciences' value of 12.97% is 4.3% above this benchmark. Historically, Cohance Lifesciences' own EBITDA Margin % has ranged from 19.03 to 54.83 over the past decade. While the company's 10-year median is 46.46 vs. the industry median of 12.44, Cohance Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cohance Lifesciences's current EBITDA Margin % of 12.97% is 4.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cohance Lifesciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cohance Lifesciences's current EBITDA Margin % is 12.97%, which is 72% below median its own 10-year median of 46.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cohance Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Cohance Lifesciences (BOM:543064) is currently considered Possible Value Trap. The stock's GF Value™ is ₹695.81, compared to a current price of ₹425.40 — trading 38.9% below its estimated fair value. The current EBITDA Margin % is 12.97%, which is 72% below median its 10-year median of 46.46 and 4.3% above the Drug Manufacturers industry median of 12.44. Cohance Lifesciences' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cohance Lifesciences (BOM:543064), the current EBITDA Margin % is 12.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cohance Lifesciences (BOM:543064) Overvalued in 2026?
Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued.
The current stock price of ₹425.40 is trading 38.9% below its estimated GF Value™ of ₹695.81.
GuruFocus considers Cohance Lifesciences to be Possible Value Trap.
Key valuation signals for BOM:543064:
EBITDA Margin %: 12.97% (72% below median its 10-year median of 46.46)
GF Value™: ₹695.81 vs. price of ₹425.40 (38.9% below fair value)
Industry Position: 4.3% above the Drug Manufacturers median (#325 of 961)
No single metric tells the full story. See the BOM:543064 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
87GF Score
Get the complete analysis for BOM:543064
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543064 has been successfully added to your 
